Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelira Therapeutics ( (AU:ZLD) ) has shared an update.
Zelira Therapeutics announced the publication of a clinical study demonstrating the efficacy and safety of its proprietary cannabinoid-based therapy, ZLT-L-007, in treating diabetic neuropathy. The study showed that ZLT-L-007 significantly outperformed Lyrica® (Pregabalin) in reducing pain and improving quality of life for patients, marking a potential shift in the standard-of-care treatment for diabetic neuropathy. The study, conducted under rigorous clinical standards, reported no serious adverse events, suggesting a promising future for ZLT-L-007 in the market.
More about Zelira Therapeutics
Zelira Therapeutics is a global leader in cannabinoid-based therapeutics, focusing on developing innovative treatments for various medical conditions. The company is particularly involved in creating therapies that address pain management and other symptoms associated with chronic illnesses.
Average Trading Volume: 3,615
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88M
For an in-depth examination of ZLD stock, go to TipRanks’ Stock Analysis page.